Instituto Hermes Pardini SA operates within the Medical laboratories sector. In addition to historical fundamental analyses, the complete report available to purchase compares Instituto Hermes Pardini SA with three other pharmaceutical manufacturers in Latin America: Laboratorios Richmond SACIF of ARGENTINA (2020 sales of 6.18 billion Argentinian Pesos [US$62.74 million] of which 66% was Private Market), Ouro Fino Saude Animal Participacoes SA (730.11 million Brazilian Reals [US$136.68 million] of which 74% was Production Animals), and Fleury SA (2.97 billion Brazilian Reals [US$556.29 million] of which 82% was Diagnostic Medicine).

Sales Analysis. Sales were up sharply during the second quarter of 2021 versus the previous year's second quarter. During the second quarter of 2021, sales at Instituto Hermes Pardini SA totalled 520.67 million Brazilian Reals. This is an increase of 102.5% from the 257.08 million Brazilian Reals in sales at the company during the second quarter of 2020. This was the biggest same quarter rise in sales at Instituto Hermes Pardini SA in the previous 23 quarters. During the first two quarters of 2021, sales totalled 998.16 million Brazilian Reals, which is 76.5% higher than through the first two quarters of 2020. There appears to be at least some degree of seasonality in the sales at Instituto Hermes Pardini SA: during 5 of the previous 6 years, sales were highest during the third quarter. The exception to this was during 2020, when the fourth quarter was the best quarter, accounting for 32% of sales (during that same year, the third quarter accounted for 30% of sales). During the year ended December of 2020, sales at Instituto Hermes Pardini SA were 1.49 billion Brazilian Reals (US$279.68 million). This is an increase of 10.4% versus 2019, when the company's sales were 1.35 billion Brazilian Reals. This was the fifth consecutive year of sales increases at Instituto Hermes Pardini SA (and since 2015, sales have increased a total of 94%).